Previous Article | Next Article 
Journal of Virology, December 2000, p. 11359-11366, Vol. 74, No. 23
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Recombinant Human Adenovirus: Targeting to the
Human Transferrin Receptor Improves Gene Transfer to Brain
Microcapillary Endothelium
Haibin
Xia,1
Brian
Anderson,1
Qinwen
Mao,1 and
Beverly L.
Davidson1,2,*
Program in Gene Therapy, Departments of
Internal Medicine1 and
Neurology,2 University of Iowa
College of Medicine, Iowa City, Iowa 52242
Received 23 June 2000/Accepted 30 August 2000
 |
ABSTRACT |
Some inborn errors of metabolism due to deficiencies of soluble
lysosomal enzymes cause global neurodegenerative disease. Representative examples include the infantile and late infantile forms
of the ceroid lipofuscinoses (CLN1 or CLN2 deficiency, respectively) and mucopolysaccharidoses type VII (MPS VII), a deficiency of
-glucuronidase. Treatment of the central nervous system component of
these disorders will require widespread protein or enzyme replacement, either through dissemination of the protein or through dissemination of
a gene encoding it. We hypothesize that transduction of brain microcapillary endothelium (BME) with recombinant viral vectors, with
secretion of enzyme product basolaterally, could allow for widespread
enzyme dissemination. To achieve this, viruses should be modified to
target the BME. This requires (i) identification of a BME-resident
target receptor, (ii) identification of motifs targeted to that
molecule, (iii) the construction of modified viruses to allow for
binding to the target receptor, and (iv) demonstrated transduction of
receptor-expressing cells. In proof of principal experiments, we chose
the human transferrin receptor (hTfR), a molecule found at high density
on human BME. A nonamer phage display library was panned for motifs
which could bind hTfR. Forty-three clones were sequenced, most of which
contained an AKxxK/R, KxKxPK/R, or KxK motif. Ten peptides
representative of the three motifs were cloned into the HI loop of
adenovirus type 5 fiber. All motifs tested retained their ability to
trimerize and bind transferrin receptor, and seven allowed for
recombinant adenovirus production. Importantly, the fiber-modified
viruses facilitated increased gene transfer (2- to 34-fold) to hTfR
expressing cell lines and human brain microcapillary endothelia
expressing high levels of endogenous receptor. Our data indicate that
adenoviruses can be modified in the HI loop for expanded tropism to the hTfR.
 |
INTRODUCTION |
Many inherited metabolic disorders
lead to central nervous system (CNS) deficits, either alone or in
combination with systemic involvement (24). One approach to
metabolic correction is by cellular transduction with virus vectors
encoding a functional cDNA. For correction of the CNS component,
therapies will likely require direct application to brain parenchyma,
since closure of the blood-brain barrier (BBB) shortly after birth
would restrict entry of the gene product or gene transfer vectors into
the brain. In metabolic disorders due to deficiencies in soluble
lysosomal proteins, genetic correction of all affected cells will not
be required; secretion of overexpressed protein provides a pool of available enzyme for distribution to surrounding cells
(cross-correction). Examples of such disorders include the ceroid
lipofuscinoses I and II and mucopolysaccharidoses type VII (MPS VII).
But even with cross-correction, spread of enzyme is limited. Thus, an
important remaining problem for clinical application is how to affect
global correction in these disorders.
Earlier studies using MPS VII mouse models (deficient in the lysosomal
enzyme
-glucuronidase) have allowed testing of potential therapies
for both the CNS and visceral components of this representative disease. Direct intraparenchymal gene transfer to mouse brain with
adenovirus vectors expressing
-glucuronidase allowed for extensive
distribution of enzyme and correction of the characteristic storage
defect within the brains of
-glucuronidase-deficient mice (13,
29). The spread of enzyme beyond sites of transduction resulted
from secretion of
-glucuronidase upon overexpression, with uptake
and correction by nontransduced cells. Similar results were found with
recombinant adeno-associated virus (25, 27, 31) and
lentivirus (2) vectors expressing
-glucuronidase. Due to
the larger size of a primate brain, however, focal gene delivery is
unlikely to result in significant amounts of secreted enzyme reaching
areas remote from the site of vector injection. An alternative to
direct injection into the brain parenchyma for correction of global
neurodegenerative disease would be to take advantage of the vasculature
of the host. One approach could be to disrupt the tight junctions of
the vascular endothelia for direct vector access to the underlying
parenchyma. A second could be to transduce the vascular endothelium
directly. For
-glucuronidase, which is capable of being secreted
basolaterally from vascular endothelium (B.L.D., unpublished
observations), distribution into the subpial and perivascular spaces
(Virchow-Robin spaces) lining the penetrating blood vessels could allow
access to the parenchyma since the pia does not form an impermeable barrier.
In earlier studies, we found that BBB disruption does not result in
adequate vector access to parenchymal tissues. Our data showed that
only several hundred cells could be transduced upon delivery of virus
to mannitol-disrupted tight junctions (7). Rather than
delivery of virus through disrupted tight junctions (7, 20),
we propose to take advantage of the transferrin receptor (TfR) present
on brain vascular endothelium. Human TfR (hTfR), a type II membrane
protein, has been extensively characterized and consists of two
identical 95-kDa subunits linked convalently by two disulfide bonds
(30). In vitro, in vivo, and ex vivo studies by Pardridge
and others showed that antibody or transferrin conjugates with
specificity for the TfR allowed for delivery of substances to brain
capillary endothelial cells (4, 12, 21, 26). We hypothesized
that adenoviruses with motifs targeting the TfR could also allow for
transduction of the brain microcapillary endothelium (BME).
Modification of the virus for targeting to the TfR could be
accomplished through bifunctional antibodies or by genetically modifying the virus to display a specific TfR binding motif. Douglas et
al. and others have reported the feasibility of using bifunctional antibodies for targeting in vitro (9, 16, 32, 34, 36). Experiments also showed that adenovirus capsids modified to contain a
carboxyl-terminal polylysine tract allowed for improved gene transfer
to many cell types via facilitated binding to cell surface heparan
sulfate proteoglycans (3, 14, 28, 33, 35). Alteration of the
HI loop of fiber to express an RGD motif, a sequence normally found in
the penton base of adenovirus type 5 (Ad5), also improved binding to
integrin-expressing cells (23).
Because of its relative simplicity we used phage display screening to
identify epitopes specific to the TfR and then introduced the sequences
encoding these peptides directly into the HI loop of Ad5 fiber.
Modified recombinant adenoviruses were then tested for their ability to
transduce TfR-expressing cell lines and human BME cells.
 |
MATERIALS AND METHODS |
Cell culture.
All media were supplemented with 10% fetal
bovine serum (FBS) unless otherwise indicated. Human embryonic kidney
cells (HEK 293) were maintained in Dulbecco's modified Eagle's medium
(DMEM). Chinese hamster ovary cell (CHO) cells expressing human
transferrin receptor (a kind gift from Martin Lawrence, Harvard
University, Cambridge, Mass.), were maintained in F-12 Nutrient
Mixture. HeLa cells (obtained from the American Type Culture Collection
(ATCC), Rockville, Md.) were grown in minimal essential medium (MEM). The human prostate cancer cell line T24 was also from the ATCC and was
maintained in 1640 medium. Human BME cells (kindly provided by Jay
Nelson, Oregon Health Sciences University) were grown in 10% human AB
serum (Sigma-Aldrich, St. Louis, Mo.) and in EBM (Clonetics,
Walkersville, Md.).
Phage screening.
Ten microliters of amplified nonapeptide
phage library (a generous gift from Al Jesaitis, Montana State
University) was screened against the purified extracellular domain of
hTfR (kindly provided by Martin Lawrence, Harvard University) coated on
96-well microtiter plates in 100 µl of 0.05 M carbonate buffer (pH
9.6). In the first panning, hTfR was coated at 100 µg/ml. Subsequent
pannings were done with decreasing concentrations of hTfR for increased
stringency (10 and 1 µg/ml for the second and third pannings,
respectively). Bound phage were eluted with low-acid buffer (0.1 M
glycine, pH 2.2) or ligand (iron-loaded human transferrin;
Sigma-Aldrich) in TBS buffer (50 mM Tris-Cl, pH 7.5; 150 mM NaCl).
After three successive rounds of panning and amplification, clones were
picked and sequenced as described elsewhere (5). All
sequencing was performed in the University of Iowa DNA sequencing facility.
Phage and peptide binding assays.
The extracellular domain
of the hTfR was coated on 96-well microtiter well plates in 150 µl of
0.05 M carbonate buffer (pH 9.6) overnight (ON). The plates were then
blocked (200 µl, 3% bovine serum albumin [BSA] for 2 h),
washed, and incubated with purified phage (1010 phage) B1,
B2, or a sequenced random clone from the library for 1 h at room
temperature. Plates were washed and incubated with a rabbit anti-fd
bacteriophage biotin conjugate (Sigma-Aldrich) directed against the M13
phage. Plates were developed using extravidin-peroxidase conjugates and
diaminobenzidine (DAB) and then read at 490 nm using a microplate
reader (Molecular Devices, Sunnyvale, Calif.). Data are presented as
the mean of triplicates ± the standard error of the mean (SEM).
The experiments were repeated three times.
B2 peptide binding was tested for specificity for hTfR in two separate
assays. For both, hTfR was first coated onto 96-well plates. In one
assay, plates were coated ON with 3.75 µl of hTfR in 150 µl,
blocked, and washed, followed by the addition of 100 µl of peptide B2
conjugated to biotin (Genosys Biotechnologies, Inc., Woodlands, Tex.)
at a concentration range of 500 to 62.5 µg/ml. In the second assay
plates were coated with 150 µl of hTfR (range, 25 to 1.6 µg/ml).
After overnight coating, wells were blocked and then incubated with
B2-labeled biotin (25 µg). Plates were developed and read as
described above. Data are presented as the means of triplicates ± the SEM. The experiments were repeated three times.
Construction of recombinant plasmids.
To facilitate the
generation of HI loop-modified viruses, the Ad5 fiber gene was first
cloned into the vaccinia virus expression vector pTM1 (a kind gift from
Michael J. Welsh, University of Iowa) by PCR amplification. This
plasmid was designated pTM1Ad5fiber. Unique restriction sites and the
B2 sequence were then introduced into fiber. To accomplish this, two
pairs of primers, F1 (5'-AGAAATGGAGATCTTACTGAAGGC-3') and R1
(5'-CCCCTTCGGCCTCTTCACCTTATGACCAGTTGTGTCTCCTGTTTCCTGTGTACC-3') and also F2
(5'-GGTCATAAGGTGAAGAGGCCGAAGGGGCCAAGTGCATACTCTATGTCATTTTCA-3') and R2
(5'-AACCCCGGGACTAGTCTATTCTTGGGCAATGTATGAAAAAGTGTA-3'), were
used to amplify a 210- and a 100-bp fragment of Ad5 fiber using
purified virus genomic DNA as a template. The reaction products were
gel purified and mixed, and contiguous sequences were generated by
overlapping PCR using primers F1 and R2. The PCR amplification product
contained a unique BglII site at the 5' end and 3'
SpeI and SmaI sites. The restricted fragment was
cloned into BglII- and SmaI-restricted pTM1Ad5
fiber. The resultant plasmid was named pTM1Ad5fiber/B2HI. All other
motifs were similarly introduced using specific primer pairs. These
plasmids were named pTM1Ad5fiber/B1HI, etc., and were used in in vitro
expression systems to analyze the effects of the epitopes on fiber
trimerization or binding to hTfR.
A shuttle was developed to allow insertion of modified HI loops into
Ad5 fiber sequences. First, pTG1696 (obtained from Transgene
S.A.,
Strasbourg, France) was cut by
NotI and
SpeI to
remove approximately
8,000 bp of the first half of the plasmid. The
plasmid was reclosed
to generate pTGSN53 and contained adenovirus
sequences from bp
29510 to 35935. pTM1Ad5fiber/B2HI was cut by
SphI and
SmaI, and
the fragment was cloned into
pTGSN53 to obtain pTGSS/B2HI plasmids.
To facilitate homologous
recombination in
Escherichia coli, we
next introduced more
than 1.0 kb of adenovirus sequence at the
3' end of the fiber sequence.
The primers Fbs (5'-CCC
ACTAGTATCGTTTGTGTT-3')
and Rbs (5'-AAA
GGATCCAGATCTGTTTGTCACGCCGCG-3')
were used to amplify
a fragment containing
SpeI and
BamHI restriction sites (underlined)
at the 5' and 3' ends
of the fragment, respectively, using Ad5
genomic DNA as a template. The
PCR product was cut by
BamHI and
SpeI and then
cloned into pTGSS/B2HI. The resulting plasmid was
designated pBS/B2HI
(additional details and maps are available
upon request). pBS/B2HI
contains the hTfR-targeting peptide B2
in the HI loop of Ad5 fiber and
the novel
SpeI site at the end
of fiber coding sequence.
Moreover, this plasmid also has greater
than 1 kb of flanking Ad5 DNA
sequence on either side of the fiber.
pBS/B2HI will be useful for the
cloning of any identified motif
into the HI loop or for the generation
of chimeric fiber
sequences.
For plasmids pBS/B1HI, pBS/B3HI, etc., overlapping PCR was used to
generated fragments containing motifs B1 and B3 to B10.
These fragments
were cut with
SpeI and
SphI and cloned into
similarly
cut pBS/B2HI to generate pBS/BxHI. Sequences for overlapping
PCR
are available upon
request.
A full-length adenovirus backbone plasmid for recombination with
pBS/BxHI was also generated. The plasmid pTG3602 (Transgene
S.A.),
which contains a wild-type fiber sequence, was modified
to contain a
unique
SwaI site in fiber to facilitate homologous
recombination. To accomplish this, pTG3602 was partially digested
by
NdeI and then ligated with an
NdeI linker
5'-TACGCCCC
ATTTAAATGG-3'
containing an
SwaI site (underlined). The plasmid was designated
pTG3602/SwaI. pTG3602/SwaI was cut with
ClaI and
cotransformed
into
E. coli BJ5183 with
ScaI-linearized pacAd5RSVGFP (
1) to
generate
pTG3602RSVGFP/SwaI. Positive clones were screened by
enzyme
digestion and sequencing. A 4.6-kb
BamHI and
NotI
restriction
fragment was liberated from pBS/BxHI and cotransformed with
SwaI-linearized
pTG3602RSVGFP/SwaI into
E. coli
BJ5183 to generate pTG3602RSVGFP/BxHI
(pAd5GFPBxHI; see Fig.
5).
Viruses.
Ad5GFP, with GFP under the control of Rous sarcoma
virus (RSV) promoter, was from the Gene Transfer Vector Core,
University of Iowa. hTfR-targeting viruses were generated by
transfection of HEK 293 cells with PacI-digested
peptide-modified virus vectors (6). pAd5GFPBxHI (10 to 15 µg) were digested with 16 U of PacI at 37°C for 2 h. The DNA was precipitated and transfected into HEK 293 cells using
calcium phosphate (15). After 5 to 10 days, the lysates were
harvested and further propagated on HEK 293 cells. Finally, viruses
were purified by centrifugation in CsCl gradients according to standard
protocols. Virus particle titers were determined spectrophotometrically
(18). The viruses were named Ad5GFPBxHI, where "x" is
the epitope number (B1, B2, etc.).
Fiber trimerization assays.
Fifty to 70% confluent HeLa
cells in 150-mm plates were rinsed with serum-free MEM and then
incubated with vaccinia virus VTF7-3 at a multiplicity of infection of
10 (a kind gift from Michael J. Welsh, University of Iowa) in 3 ml of
MEM at 37°C for 1 h. Cells were washed and then transfected by
pTM1Ad5fiber/BxHI plasmids or pTM1Ad5fiber (wild-type fiber) (10 µg)
using Lipofectin (Gibco). After transfection, cells were rinsed and
incubated in 30 ml of MEM-10% FBS at 37°C. The lysates were
harvested 16 to 24 h later for trimerization assays. A 10-µl
aliquot of lysate containing the recombinant proteins was subjected to
reducing (31.25 mM Tris-Cl, pH 6.8; 1% sodium dodecyl sulfate [SDS];
2.5% 2-mercaptoethanol [2-ME]; 10% glycerol) or nonreducing (the
same except no 2-ME) conditions and fractionated by SDS-12%
polyacrylamide gel electrophoresis (PAGE). The fractionated protein was
transferred onto nitrocellulose membranes and probed by anti-fiber
monoclonal antibody 4D2.5 (kindly provided by J. Engler, University of
Alabama, Birmingham) (17). The film was developed using an
ECL Kit (Amersham Pharmacia Biotech, Piscataway, N.J.) according to the
manufacturer's recommendations.
TfR binding assays with Bx targeting motifs in context of
fiber.
Protein G-conjugated agarose beads (60 µl; Pharmacia)
were incubated with 15 µg of monoclonal antibody 128.1 directed
against hTfR (generously provided by Ian Trowbridge, The Salk
Institute, San Diego, Calif.). The 128.1-conjugated beads were
resuspended in dilution buffer (10 mM Tris-Cl [pH 8.0], 140 mM
NaCl, 0.1% Triton X-100, 0.1% BSA) and incubated with 15 µg of
soluble hTfR for 1.5 h at 4°C. The complex was then incubated
with 100 µl of vaccinia virus lysates containing wild-type or
BxHI-modified fibers for 1.5 h at 4°C. The complexes were
sequentially washed
twice with dilution buffer, twice with TSA buffer
(10 mM Tris-Cl, pH 8.0; 140 mM NaCl), and once with 50 mM Tris-Cl (pH
6.8). The samples were denatured at 95°C for 3 min, followed by
microcentrifugation. The disrupted complex was fractionated by SDS-PAGE
and transferred to nitrocellulose membranes. Membranes were probed
using 4D2.5 monoclonal antibody directed against an epitope in the Ad5
fiber tail (17). The experiments were repeated three times.
Transduction of TfR+ cells.
Experiments were
carried out similarly to those described by Wickham et al.
(33). hTfR+ CHO cells, human prostate cancer T24
cells, or human brain endothelial cells (105) were
incubated with Ad5GFPBxHI or Ad5GFP (4 × 108
particles in 1 ml of DMEM-2% FBS) for 1 hour at 37°C. The cells were then washed three times with 2% FBS-DMEM, followed by incubation for 48 h at 37°C. The cells were then detached by trypsin and analyzed by using a fluorescence-activated cell sorter (FACS) at the
University of Iowa FACS facility. In blocking experiments, hTfR+ CHO cells or T24 cells were incubated with human
iron-loaded transferrin (40 µg/ml in 1 ml of DMEM-2% FBS) or
soluble hTfR (15 µg/ml in 1 ml) for 30 min at 4°C before the
addition of virus. Human brain endothelial cells were incubated with
human iron-loaded transferrin (40 µg/ml in 1 ml) for 30 min at 4°C
before the addition of virus. Data are presented as the means of
triplicates ± the SEM. The experiments were repeated three times.
Immunohistochemistry.
T24 and BME cells were grown on 60-mm
dishes, fixed in 2% paraformaldehyde, washed with PBS, and incubated
with primary antibody (128.1 diluted 1:200 in PBS, 3% BSA, 0.3%
Triton X-100, and 0.02% sodium azide) ON at 4°C. Plates were washed
and incubated in rhodamine-conjugated goat anti-mouse (1:400) for
1 h at room temperature. Positive cells were visualized using an
Olympus IX70 microscope, and images were captured using a SPOT RT
digital camera.
 |
RESULTS |
hTfR targeting motifs.
The efficiency of adenovirus
infection depends on the level of the coxackie adenovirus receptor
(CAR) expression. However, the tropism of Ad5 can be modified using
genetic methods (23, 33). As a first step toward
extending the tropism of Ad5 to BME for use in CNS gene
therapy, we screened a nonapeptide phage display library
(5) against the extracellular domain of hTfR (30), a receptor found at high density on the BME.
Enzyme-linked immunosorbent assay (ELISA) plates were coated with
soluble hTfR, and bound phage were eluted by a low-pH buffer. Eluted
phage were amplified in E. coli K91 and subsequently
screened again for binding to the immobilized hTfR. In separate
experiments, bound phage were eluted with purified transferrin
holoenzyme. Three rounds of screening-amplification were done
for each type of elution. From two independent experiments,
a total of 43 clones were isolated, most from acid elution.
Sequencing of isolated phage revealed the peptide motifs
AKxxK/Rx, KxKxPK/R, or KxK in 31 of the clones (Table
1). Some clones were isolated more than
once, arising from independent experiments and different elution
parameters. GHKVKRPKG and IEAYAKKRK motifs were
isolated 10 and 7 times, respectively. The peptide sequence
KDKIKMDKK was present in four clones, while KNKIPKSPK was isolated
twice. Only several peptides contained amino acid arrays identical to
regions of human transferrin (Table 1), indicating that most motifs
were likely conformational, rather than linear epitopes.
To test the specificity of peptide binding for human TfR, two motifs
were randomly chosen: IEAYAKKRK (B1) and GHKVKRPKG (B2).
First,
phage expressing the B1 or B2 peptide and randomly isolated
control
phage (R) were subjected to large-scale amplification,
followed by
incubation with immobilized hTfR. Both B1 and B2 bound
hTfR in contrast
to control phage (Fig.
1). Binding of the
B2
peptide motif to hTfR, independent of the phage sequences, was
also
tested. Biotinylated B2 was synthesized and incubated with
immobilized
hTfR using standard ELISA-based assays. The data in
Fig.
2 show that peptide B2 alone bound to
hTfR in a dose-dependent
manner.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 1.
Phage expressing the hTfR-targeting motifs B1 or B2 bind
immobilized hTfR. Amplified, purified phage containing B1, B2, or
random peptide (R) were tested for their ability to bind hTfR on
96-well microtiter plates. Bound phage were detected using anti-fd
antibodies as described in Materials and Methods. The data
represent the means ± the SEM and are representative of three
independent experiments.
|
|

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 2.
Peptide motif B2 binds immobilized hTfR. B2 peptide was
synthesized with an amino-terminal biotin moiety and tested for binding
specificity to hTfR using an ELISA-based assay. (A) Soluble hTfR (3.75 µg) was coated onto ELISA plates, incubated with biotin-labeled B2 at
various concentrations, and detected using extravidin as described in
Materials and Methods. (B) Soluble hTfR at various concentrations was
coated onto plates, followed by incubation with a constant
concentration of B2-biotin (25 µg). Plates were developed using
extravidin-horseradish peroxidase, followed by detection of the optical
density at 490 nm as described in the text. The data represent the
means ± the SEM from three independent experiments.
|
|
Characterization of recombinant fibers.
Motifs in phage may or
may not be indicative of the same sequence in the context of Ad5 fiber.
Moreover, the hTfR-targeting motifs could have deleterious effects on
fiber trimerization inhibiting their assembly and in turn impairing
virus capsid maturation (11, 17). To test if the identified
nonapeptides retained their ability to bind hTfR in the context of
fiber, immunoprecipitation experiments were performed. First, motifs
were cloned into the HI loop and the resultant fibers were expressed in
a mammalian expression system. Lysates containing the modified fibers
were then incubated with hTfR, and the complex was immunoprecipitated
with anti-hTfR antibodies. Western blot analysis for fiber using an
antibody to the amino-terminal region indicated that the hTfR-targeting motifs, when placed in the HI loop of fiber, maintained their ability
to bind to hTfR (Fig. 3, lanes B1 and
B2). Wild-type fiber, though present at high levels in the expressed
lysate (Fig. 3, lane WT*), was not pulled down with anti-hTfR
antibodies (Fig. 3, lane WT), demonstrating specificity of the epitopes
for the hTfR.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 3.
B2 or B1 epitopes in the HI loop of Ad5 fiber retain
their ability to bind to hTfR. Wild-type or epitope-modified Ad5 fibers
were expressed in HeLa cells using a vaccinia virus expression system
as described in Materials and Methods. The expressed fibers were
incubated with hTfR, and the complex was added to monoclonal antibody
128.1 (anti-hTfR antibody) previously adsorbed to protein G beads. The
beads were isolated, and the complex was disassociated and fractionated
by SDS-PAGE. Fibers pulled down by immunoprecipitation (lanes B1, B2,
and WT) were detected using the 4D2.5 anti-fiber antibody, which
recognizes an epitope in the tail region of the fiber (17).
Lane WT* is vaccinia virus lysate expressing wild-type fiber that was
not subjected to immunoprecipitation. The immunoblot is representative
of three independent experiments.
|
|
Lysates containing expressed, modified fibers were also used to
determine the effects of the motifs on fiber trimerization.
Other
researchers have shown that trimerization can be disrupted
by
modifications at the carboxy terminus (
17). Figure
4 shows
that B1 and B2 motifs do not
inhibit fiber trimerization. Similar
results were seen for the other
motifs (data not shown).

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 4.
Effects of hTfR-targeting motifs on fiber trimerization.
Epitope-modified Ad5 fibers were expressed in HeLa cells using a
vaccinia virus expression system as described in Materials and Methods.
The expressed fibers were subjected to reducing or nonreducing
conditions prior to sample loading. Samples were fractionated by
SDS-PAGE and blotted onto nitrocellulose. Expressed fibers were
detected with antibody 4D2.5. The results are representative of the
other hTfR-targeting motifs.
|
|
HI loop-modified viruses and gene transfer to hTfR-expressing
cells.
The generation of multiple recombinant adenoviral vectors
differing only in the HI loop could be best accomplished using the E. coli recombination system developed by Chartier et al.
(6). For our purposes, two key plasmids were developed. The
first was pBS/B2HI. This plasmid contained Ad5 fiber sequences with a
unique SpeI site at the 3' end of the fiber gene (see
Materials and Methods). This site, in combination with an internal
SphI site, allowed the subsequent introduction of all other
HI modifications (pBS/B1HI, pBS/B3HI, etc.). It is important to note
that pBS/B2HI will also allow the efficient introduction of any fiber
modification. The fiber sequences contained more than 1.0 kb of
flanking sequence for increased efficiency of recombination in E. coli.
A plasmid containing a full-length adenovirus genome with a green
fluorescent protein (GFP) expression cassette in the E1
region and a
unique
SwaI site in fiber was also generated (see
Materials
and Methods). The
SwaI site facilitated recombination
with
the pBS/BxHI plasmids (Fig.
5). The
resultant plasmids were
digested with
PacI and transfected
into HEK 293 cells. We noted
considerable variability in the length of
time from transfection
to CPE and also our ability to further amplify
the viruses once
the initial lysates were harvested. Of the 10 peptides
cloned
into the fiber of Ad5, only 7 could be amplified and purified
to
concentrations adequate for further testing. These results
indicate
that amplification of our HI loop adenoviruses required
retention of
CAR binding for adequate growth in HEK 293 cells.
Thus, the viruses
have expanded rather than targeted tropism.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 5.
Construction of recombinant adenoviruses with
hTfR-targeting motifs in the HI loop. A series of HI loop-modified
shuttle plasmids were generated (pBS/BxHI; see Materials and
Methods). These shuttles were cut with BamHI and
NotI, and the 4.6-kb fragment was cotransformed with
SwaI-cut pTG3602RSVGFP/SwaI into E. coli BJ5183. Appropriate recombination resulted in full-length Ad5
genomes with a GFP expression cassette in the E1 region and B1, B2,
etc., motifs in the HI loop. The recombinant plasmids were restricted
with PacI and transfected into HEK 293 cells, and virus was
harvested and propagated upon finding evidence of cytopathic effect.
|
|
Peptide-modified recombinant adenoviruses were tested for their ability
to transduce a CHO cell line previously transfected
with
recombinant hTfR. In this cell line, the endogenous CHO TfR
has a
51-amino-acid deletion in the cytoplasmic domain leading
to a
nonfunctional receptor (
22). Recombinant adenoviruses
containing
motifs B1 to B3 and B5 to B8 (Ad5GFPB1HI,
Ad5GFPB2HI, etc.) facilitated
gene transfer 11- to 34-fold over Ad5GFP
(Fig.
6). In all cases,
infection was
inhibited by preincubating the cells with human
transferrin, suggesting
that gene transfer with TfR motif-modified
adenoviruses occurred in
part through specific binding to the
hTfR. Preincubation of cells with
soluble hTfR corroborated these
results (Fig.
6).

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 6.
Transduction of hTfR+ CHO cells by
adenoviruses genetically modified to express hTfR-targeting epitopes.
hTfR+ CHO cells (1 × 105) were infected
by Ad5GFPB1HI, Ad5GFPB2HI, etc., or Ad5GFP (4 × 108
particles) for 1 h at 37°C, and GFP-positive cells were
quantitated by FACS 48 h later. For blocking studies, cells were
incubated with soluble hTfR (sTfR) or transferrin for 30 min at 4°C
prior to the addition of virus. The various viruses are indicated by
the TfR-targeting epitope (B1, B2, etc.). "C" corresponds to
Ad5GFP. The data are the means ± the SEM from three independent
experiments.
|
|
Ad5GFPB5HI through Ad5GFPB8HI were further tested on T24 cells, a cell
line that has high endogenous levels of hTfR (Fig.
7A) and undetectable levels of CAR as
assessed by reverse transcription-PCR
and FACS analysis
(Timothy Ratliff, unpublished observations).
All motifs directed
significant increases in gene transfer to
T24 cells (Fig.
7B). Again,
B6 and B8 epitopes were best. Ad5GFPB6HI
and Ad5GFPB8HI allowed for
transduction of 25 and 15% of cells
(subtracting the background),
respectively, a 3.9- or 2.8-fold
increase over the control virus.
Further, this increase could
be abrogated by the prior addition of
transferrin or purified
soluble hTfR (Fig.
7B).

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 7.
hTfR expression and transduction of T24 cells by
hTfR-targeting epitope modified adenoviruses. (A) Immunostaining for
hTfR expression. T24 cells were fixed and stained with monoclonal
antibody 128.1, followed by rhodamine-conjugated goat anti-mouse
antibodies. The photomicrograph is representative of the entire plate.
(B) T24 cells (1 × 105) were transduced with
Ad5GFPB5HI, Ad5GFPB6HI, etc., or Ad5GFP (4 × 108
particles), and GFP-positive cells were quantitated by FACS. For
blocking experiments T24 cells, were incubated with human soluble hTfR
or transferrin for 30 min at 4°C prior to the addition of virus. The
various viruses are indicated by the hTfR-targeting epitope
(B5, B6, etc.). "C" corresponds to Ad5GFP. The data are the
means ± the SEM and are from three independent experiments.
|
|
Human BME cells express a high level of the TfR (Fig.
8A). Initial studies showed that
these cells are poorly transduced by
recombinant adenoviruses
expressing native Ad5 fiber sequences
(Fig.
8B). However, when
Ad5GFPB6HI and Ad5GFPB8HI were tested,
gene transfer to human BME
improved 3.5- and 2.5-fold, respectively.
Again, transduction could be
inhibited by preincubation with transferrin,
indicating that the
recombinant viruses were binding and entering
BME cells via the
targeted motif.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 8.
hTfR expression and Ad5GFPB6HI- or Ad5GFPB8HI-mediated
transduction of human BME cells. (A) Expression of hTfR on human BME
cells. Cells were fixed and stained as described in Fig. 7. (B) Human
BME cells (1 × 105) were transduced with Ad5GFPB6HI,
Ad5GFPB8HI, or Ad5GFP (4 × 108 particles), and
GFP-positive cells were quantitated by FACS. For blocking experiments,
cells were incubated with transferrin for 30 min at 4°C prior to the
addition of virus. The data are the means ± the SEM and are from
three independent experiments.
|
|
 |
DISCUSSION |
In this study we tested the feasibility of targeting recombinant
viral vectors to the hTfR to transduce the BME. We took advantage of an
available phage display library to identify motifs specific to the
hTfR, and showed that these motifs did not inhibit fiber trimerization.
In many cases fiber sequences modified to express the identified motifs
in the HI loop allowed for the production of viable recombinant virus.
Importantly, the sequences retained their ability to bind to hTfR and
direct gene transfer to hTfR-expressing cells.
We found that the addition of peptide sequences into the HI loop of
fiber was not uniformly well tolerated, even among sequences which were
highly similar with regard to charge and side group. For instance,
viruses containing the peptide B2 motif were capable of being amplified
to some degree, while those containing the similar B6 motif (Table
2) had greatly improved growth
properties. Similarly, the B4 sequence was not amenable to virus
production, while the B3-containing virus grew quite well. Because we
found that fiber trimerization was not affected, the block in virus production could result from steric hindrance of CAR binding. To
overcome this problem for Ad5GFPB4HI, Ad5GFPB9HI, and Ad5GFPB10HI, amplification could be done using HEK 293 cells modified to express a
surrogate receptor, such as previously described by others (8, 10).
Interestingly, earlier reports (8, 10) demonstrated the
feasibility of using an epitope cloned into the HI loop or carboxy terminus of fiber, or penton base, to allow adenovirus binding and
entry mediated by a membrane-bound ScFv directed to that epitope. Our
data suggest that other ligand-receptor pairs may not be sufficient to
support viral production when CAR-fiber interactions are impaired. HEK
293 cells express high levels of hTfR based on Western blot analyses
and immunofluorescence microscopy (B.L.D., unpublished observations).
However, production of B2 and B8 motif-modified adenoviruses was quite
difficult even though binding to the hTfR was retained in the context
of fiber and the intact virion.
The ability of a membrane-bound ScFv versus that of a recycling
receptor-ligand pair (TfR-Tf) to serve as pseudoreceptor suggests that
differences in recycling and internalization may be important. Data
presented by Leopold and colleagues suggest that Ad5 escapes the
endosome very early after internalization, probably before endosome-endosome fusion (19). It is possible that some HI
loop-modified adenoviruses are impaired in their ability to direct
early endosomal release, thereby allowing for some recycling and
release of virus at the cell surface.
The B6 and B8 targeting motifs in recombinant adenovirus significantly
improved gene transfer to hTfR+ CHO cells, T24 cells, and
human BME cells. Also, both were more effective than the other motifs
tested. The B2 epitope in Ad5GFPB2HI, which was only tested on
hTfR+ CHO cell lines, has an amino acid sequence similar to
that of B6. When cloned into adenovirus, both Ad5GFPB2HI and Ad5GFPB6HI resulted in an approximately 34-fold increase in gene transfer. The
differences between the B2 and the B6 motifs are a valine in the +4
position (versus alanine), an arginine in the +6 position (versus
glycine), a lysine in the +8 position (versus arginine), and a glycine
in the +9 position (versus lysine). In cloning the B5-B8 epitopes into
fiber, an amino-terminal glycine and a carboxyl-terminal LGS linker
(relative to the nonapeptide sequence) was added. Thus, the linker did
not appear to further improve or inhibit hTfR targeting. However, and
importantly, the addition of the linker did facilitate virus growth as
previously discussed.
At the outset of our studies, we expected that epitopes isolated by
ligand elution would yield better results when cloned into the HI loop
of fiber compared to those identified using acid wash. Our data show
that the B3, B5, B7, and B8 sequences, identified by acid elution,
facilitated adenovirus-mediated transduction to hTfR-expressing cells
ca. 1.4-fold less effectively (on average) than did B6, B1, and B2.
However, both B1 and B2 were identified by acid and transferrin
elution, suggesting that there is only modest correlation between
elution parameters and the ability of that motif to facilitate receptor
targeting, at least for the hTfR.
Targeting recombinant virus vectors to a receptor expressed at high
density on BME cells is a first step toward testing if the vascular
system can be used to facilitate a global distribution of enzyme to the
CNS for inhibition or reversal of neurodegeneration. If sufficient
levels of transduction to the endothelia could be accomplished,
basolateral secretion would provide a source of enzyme to an extensive
area of the brain. In brains of larger animal models or in humans, such
an approach would bypass the requirement of multiple parenchymal
injections, which could result only in small, nonoverlapping spheres of correction.
In summary, our data suggest that several short motifs, when cloned
into the HI loop of fiber, can support hTfR-targeted transduction with
recombinant adenovirus vectors. It will be interesting to determine if
these epitopes can also be used to improve gene transfer of other
encapsidated viruses, such as adeno-associated virus.
 |
ACKNOWLEDGMENTS |
We thank Richard D. Anderson and Joseph Zabner for
critical discussions and Christine McLennan for secretarial assistance.
This study was supported by the American Heart Association (H.X.), the
State of Iowa Biosciences Initiative (Q.M.), and the National
Institutes of Health (HD33531 and DK54759). B.L.D. is a fellow of the
Roy J. Carver Trust.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Internal Medicine and Neurology, 200 EMRB, University of Iowa College of Medicine, Iowa City, IA 52242. Phone: (319) 353-5511. Fax: (319)
353-5572. E-mail: beverly-davidson{at}uiowa.edu.
 |
REFERENCES |
| 1.
|
Anderson, R. D.,
R. E. Haskell,
H. Xia,
B. J. Roessler, and B. L. Davidson.
2000.
A simple method for the rapid generation of recombinant adenovirus vectors.
Gene Ther.
7:1034-1038[CrossRef][Medline].
|
| 2.
|
Bosch, A.,
E. Perret,
N. Desmaris,
D. Trono, and J. M. Heard.
2000.
Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer.
Hum. Gene Ther.
11:1139-1150[CrossRef][Medline].
|
| 3.
|
Bouri, K.,
W. G. Feero,
M. M. Myerburg,
T. J. Wickham,
I. Kovesdi,
E. P. Hoffman, and P. R. Clemens.
2000.
Polylysine modification of adenoviral fiber protein enhances muscle cell transduction.
Hum. Gene Ther.
10:1633-1640.
|
| 4.
|
Broadwell, R. D.,
M. J. Baker-Cairns,
P. M. Friden,
C. Oliver, and J. C. Villegas.
1996.
Transcytosis of protein through the mammalian cerebral epithelium and endothelium. III. Receptor-mediated transcytosis through the blood-brain barrier of blood-borne transferrin and antibody against the transferrin receptor.
Exp. Neurol.
142:47-65[CrossRef][Medline].
|
| 5.
|
Burritt, J. B.,
M. T. Quinn,
M. A. Jutila,
C. W. Bond, and A. J. Jesaitis.
1995.
Topological mapping of neutrophil cytochrome b epitopes with phage-display libraries.
J. Biol. Chem.
270:16974-16980[Abstract/Free Full Text].
|
| 6.
|
Chartier, C.,
E. Degryse,
M. Gantzer,
A. Dieterle,
A. Pavirani, and M. Mehtali.
1996.
Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli.
J. Virol.
70:4805-4810[Abstract].
|
| 7.
|
Doran, S. E.,
X. D. Ren,
A. L. Betz,
M. A. Pagel,
E. A. Neuwelt,
B. J. Roessler, and B. L. Davidson.
1995.
Gene expression from recombinant viral vectors in the central nervous system after blood-brain barrier disruption.
Neurosurgery
36:965-970[Medline].
|
| 8.
|
Douglas, J. T.,
C. R. Miller,
M. Kim,
I. Dmitriev,
G. Mikheeva,
V. Krasnykh, and D. T. Curiel.
1999.
A system for the propagation of adenoviral vectors with genetically modified receptor specificities.
Nat. Biotechnol.
17:470-475[CrossRef][Medline].
|
| 9.
|
Douglas, J. T.,
B. E. Rogers,
M. E. Rosenfeld,
S. I. Michael,
M. Feng, and D. T. Curiel.
1996.
Targeted gene delivery by tropism-modified adenoviral vectors.
Nat. Biotechnol.
14:1574-1578[CrossRef][Medline].
|
| 10.
|
Einfeld, D. A.,
D. E. Brough,
P. W. Roelvink,
I. Kovesdi, and T. J. Wickham.
1999.
Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base.
J. Virol.
73:9130-9136[Abstract/Free Full Text].
|
| 11.
|
Falgout, B., and G. Ketner.
1988.
Characterization of adenovirus particles made by deletion mutants lacking the fiber gene.
J. Virol.
62:622-625[Abstract/Free Full Text].
|
| 12.
|
Friden, P. M.,
T. S. Olson,
R. Obar,
L. R. Walus, and S. D. Putney.
1996.
Characterization, receptor mapping and blood-brain barrier transcytosis of antibodies to the human transferrin receptor.
J. Pharmacol. Exp. Ther.
278:1491-1498[Abstract/Free Full Text].
|
| 13.
|
Ghodsi, A.,
C. Stein,
T. Derksen,
G. Yang,
R. D. Anderson, and B. L. Davidson.
1998.
Extensive -glucuronidase activity in murine CNS after adenovirus mediated gene transfer to brain.
Hum. Gene Ther.
9:2331-2340[Medline].
|
| 14.
|
Gonzalez, R.,
R. Vereecque,
T. J. Wickham,
M. Vanrumbeke,
I. Kovesdi,
F. Bauters,
P. Fenaux, and B. Quesnel.
1999.
Increased gene transfer in acute myeloid leukemic cells by an adenovirus vector containing a modified fiber protein.
Gene Ther.
6:314-320[CrossRef][Medline].
|
| 15.
|
Graham, F. L., and A. J. van der Eb.
1973.
A new technique for the assay of infectivity of human adenovirus 5 DNA.
Virology
52:456-467[CrossRef][Medline].
|
| 16.
|
Harari, O. A.,
T. J. Wickham,
C. J. Stocker,
I. Kovesdi,
D. M. Segal,
T. Y. Huehns,
C. Sarraf, and D. O. Haskard.
1999.
Targeting an adenoviral gene vector to cytokine-activated vascular endothelium via E-selectin.
Gene Ther.
6:801-807[CrossRef][Medline].
|
| 17.
|
Hong, J. S., and J. A. Engler.
1996.
Domains required for assembly of adenovirus type 2 fiber trimers.
J. Virol.
70:7071-7078[Abstract/Free Full Text].
|
| 18.
|
Ishibashi, M., and J. V. Maizel, Jr.
1974.
The polypeptides of adenovirus. VI. Early and late glycopolypeptides.
Virology
58:345-361[CrossRef][Medline].
|
| 19.
|
Leopold, P. L.,
G. Kreitzer,
N. Miyazawa,
S. Rempel,
K. K. Pfister,
E. Rodriguez-Boulan, and R. G. Crystal.
2000.
Dynein- and microtubule-mediated translocation of adenovirus serotype 5 occurs after endosomal lysis.
Hum. Gene Ther.
11:151-165[CrossRef][Medline].
|
| 20.
|
Nilaver, G.,
L. L. Muldoon,
R. A. Kroll,
M. A. Pagel,
X. O. Breakefield,
B. L. Davidson, and E. A. Neuwelt.
1995.
Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption.
Proc. Natl. Acad. Sci. USA
92:9829-9833[Abstract/Free Full Text].
|
| 21.
|
Pardridge, W. M.,
J. L. Buciak, and P. M. Friden.
1991.
Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo.
J. Pharmacol. Exp. Ther.
259:66-70[Abstract/Free Full Text].
|
| 22.
|
Recht, L. D.,
V. Raso,
R. Davis, and R. Salmonsen.
1996.
Immunotoxin sensitivity of Chinese hamster ovary cells expressing human transferrin receptors with differing internalization rates.
Cancer Immunol. Immunother.
42:357-361[CrossRef][Medline].
|
| 23.
|
Reynolds, P.,
I. Dmitriev, and D. Curiel.
1999.
Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector.
Gene Ther.
6:1336-1339[CrossRef][Medline].
|
| 24.
|
Scriver, C. R., et al.
1989.
The metabolic basis of inherited disease.
McGraw-Hill Book Company, New York, N.Y.
|
| 25.
|
Sferra, T. J.,
G. Qu,
D. McNeely,
R. Rennard,
K. R. Clark,
W. D. Lo, and P. R. Johnson.
2000.
Recombinant adeno-associated virus-mediated correction of lysosomal storage within the central nervous system of the adult mucopolysaccharidosis type VII mouse.
Hum. Gene Ther.
11:507-519[CrossRef][Medline].
|
| 26.
|
Shin, S.-U.,
P. Friden,
M. Moran,
T. Olson,
Y.-S. Kang,
W. M. Pardridge, and S. L. Morrison.
1995.
Transferrin-antibody fusion proteins are effective in brain targeting.
Proc. Natl. Acad. Sci. USA
92:2820-2824[Abstract/Free Full Text].
|
| 27.
|
Skorupa, A. F.,
K. J. Fisher,
J. M. Wilson,
M. K. Parente, and J. H. Wolfe.
1999.
Sustained production of -glucuronidase from localized sites after AAV vector gene transfer results in widespread distribution of enzyme and reversal of lysosomal storage lesions in a large volume of brain in mucopolysaccharidosis VII mice.
Exp. Neurol.
160:17-27[CrossRef][Medline].
|
| 28.
|
Staba, M. J.,
T. J. Wickham,
I. Kovesdi, and D. E. Hallahan.
2000.
Modifications of the fiber in adenovirus vectors increase tropism for malignant glioma models.
Cancer Gene Ther.
7:13-19[CrossRef][Medline].
|
| 29.
|
Stein, C. S.,
A. Ghodsi,
T. Derksen, and B. L. Davidson.
1999.
Systemic and central nervous system correction of lysosomal storage in mucopolysaccharidosis type VII mice.
J. Virol.
73:3424-3429[Abstract/Free Full Text].
|
| 30.
|
Testa, U.,
E. Pelosi, and C. Peschle.
1993.
The transferrin receptor.
Crit. Rev. Oncog.
4:241-276[Medline].
|
| 31.
|
Watson, G. L.,
J. N. Sayles,
C. Chen,
S. S. Elliger,
C. A. Elliger,
N. R. Raju,
G. J. Kurtzman, and G. M. Podsakoff.
1998.
Treatment of lysosomal storage disease in MPS VII mice using a recombinant adeno-associated virus.
Gene Ther.
5:1642-1649[CrossRef][Medline].
|
| 32.
|
Wickham, T. J.,
D. Haskard,
D. Segal, and I. Kovesdi.
1997.
Targeting endothelium for gene therapy via receptors up-regulated during angiogenesis and inflammation.
Cancer Immunol. Immunother.
45:149-151[CrossRef][Medline].
|
| 33.
|
Wickham, T. J.,
P. W. Roelvink,
D. E. Brough, and I. Kovesdi.
1996.
Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types.
Nat. Biotechnol.
14:1570-1573[CrossRef][Medline].
|
| 34.
|
Wickham, T. J.,
D. M. Segal,
P. W. Roelvink,
M. E. Carrion,
A. Lizonova,
G. M. Lee, and I. Kovesdi.
1996.
Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies.
J. Virol.
70:6831-6838[Abstract/Free Full Text].
|
| 35.
|
Wickham, T. J.,
E. Tzeng,
L. L. II. Shears,
P. W. Roelvink,
Y. Li,
G. M. Lee,
D. E. Brough,
A. Lizonova, and I. Kovesdi.
1997.
Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins.
J. Virol.
71:8221-8229[Abstract].
|
| 36.
|
Yoon, S.-K.,
L. Mohr,
C. R. O'Riordan,
A. Lachapelle,
D. Armentano, and J. R. Wands.
2000.
Targeting a recombinant adenovirus vector to HCC cells using a bifunctional Fab-antibody conjugate.
Biochem. Biophys. Res. Commun.
272:497-504[CrossRef][Medline].
|
Journal of Virology, December 2000, p. 11359-11366, Vol. 74, No. 23
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Belousova, N., Mikheeva, G., Gelovani, J., Krasnykh, V.
(2008). Modification of Adenovirus Capsid with a Designed Protein Ligand Yields a Gene Vector Targeted to a Major Molecular Marker of Cancer. J. Virol.
82: 630-637
[Abstract]
[Full Text]
-
Lamfers, M. L.M., Idema, S., Bosscher, L., Heukelom, S., Moeniralm, S., van der Meulen-Muileman, I. H., Overmeer, R. M., van der Valk, P., van Beusechem, V. W., Gerritsen, W. R., Vandertop, W. P., Dirven, C. M.F.
(2007). Differential Effects of Combined Ad5-{Delta}24RGD and Radiation Therapy in In vitro versus In vivo Models of Malignant Glioma. Clin. Cancer Res.
13: 7451-7458
[Abstract]
[Full Text]
-
Palermo, L. M., Hafenstein, S. L., Parrish, C. R.
(2006). Purified feline and canine transferrin receptors reveal complex interactions with the capsids of canine and feline parvoviruses that correspond to their host ranges.. J. Virol.
80: 8482-8492
[Abstract]
[Full Text]
-
Meier, O., Gastaldelli, M., Boucke, K., Hemmi, S., Greber, U. F.
(2005). Early Steps of Clathrin-Mediated Endocytosis Involved in Phagosomal Escape of Fc{gamma} Receptor-Targeted Adenovirus. J. Virol.
79: 2604-2613
[Abstract]
[Full Text]
-
Baker, A. H., Kritz, A., Work, L. M., Nicklin, S. A.
(2005). Cell-selective viral gene delivery vectors for the vasculature. Exp Physiol
90: 27-31
[Abstract]
[Full Text]
-
Fontana, L., Nuzzo, M., Urbanelli, L., Monaci, P.
(2003). General Strategy for Broadening Adenovirus Tropism. J. Virol.
77: 11094-11104
[Abstract]
[Full Text]
-
Meier, O., Boucke, K., Hammer, S. V., Keller, S., Stidwill, R. P., Hemmi, S., Greber, U. F.
(2002). Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake. JCB
158: 1119-1131
[Abstract]
[Full Text]
-
Belousova, N., Krendelchtchikova, V., Curiel, D. T., Krasnykh, V.
(2002). Modulation of Adenovirus Vector Tropism via Incorporation of Polypeptide Ligands into the Fiber Protein. J. Virol.
76: 8621-8631
[Abstract]
[Full Text]
-
Dmitriev, I. P., Kashentseva, E. A., Curiel, D. T.
(2002). Engineering of Adenovirus Vectors Containing Heterologous Peptide Sequences in the C Terminus of Capsid Protein IX. J. Virol.
76: 6893-6899
[Abstract]
[Full Text]
-
Law, L. K., Davidson, B. L.
(2002). Adenovirus Serotype 30 Fiber Does Not Mediate Transduction via the Coxsackie-Adenovirus Receptor. J. Virol.
76: 656-661
[Abstract]
[Full Text]
-
Pereboev, A., Pereboeva, L., Curiel, D. T.
(2001). Phage Display of Adenovirus Type 5 Fiber Knob as a Tool for Specific Ligand Selection and Validation. J. Virol.
75: 7107-7113
[Abstract]
[Full Text]
-
Lam, P. Y.P., Breakefield, X. O.
(2001). Potential of gene therapy for brain tumors. Hum Mol Genet
10: 777-787
[Abstract]
[Full Text]
-
White, S. J., Nicklin, S. A., Sawamura, T., Baker, A. H.
(2001). Identification of Peptides That Target the Endothelial Cell-Specific LOX-1 Receptor. Hypertension
37: 449-455
[Abstract]
[Full Text]